Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based ...

This NMA serves to bridge the gap between trials for both therapies and compare them to one another based on existing data.

Amgen's move follows the lifting of a temporary injunction on the launch of its Pavblu-branded biosimilar by the US Court of ...

With “nerves of steel,” Amgen is getting ready to sell a copycat of Regeneron’s top-selling eye drug Eylea, even as ...

Regeneron Pharmaceutical (NASDAQ:REGN) fell 4.3% after a court rejected its request for a temporary injunction blocking sales ...

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, AbbVie expanded a ...

Robert W. Baird analyst Brian Skorney maintained a Hold rating on Regeneron (REGN – Research Report) on October 22 and set a price target ...

Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg from an extension study of the Phase 3 PHOTON trial in ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,150.00.